Adam Johnson

I previously spent 11 years working on preclinical PK-PD in vivo and in vitro infection models at the University of Liverpool, mostly evaluating novel antimicrobials and antifungals. My PhD evaluated the PK-PD of novel beta-lactam-beta-lactamase inhibitor combinations to treat MDR HAP/ VAP and cUTI infections. I then moved to Centauri Therapeutics, which is an immunotherapy company focused on infectious disease. My current role is involved with the preclinical assessment of the microbiology and pharmacology of our lead compound.